Events | 2009.11.30
Phase I Study of Preventive HIV Vaccine Shows Improved Immune Responses When the Vaccine is Delivered by Electrical Impulses
NEW YORK & SAN DIEGO--(BUSINESS WIRE)--A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City. The results show that TriGrid™, a technology developed by Ichor Medical Systems, Inc., helped to enhance the immunogenicity of the vaccine tested. Compared to intramuscular injection, the conventional mode o
For more information, please visit
http://www.businesswire.com/news/home/20091130005065/en
